Skip to content

Comparison of ultrasound-guided shoulder joint multisite injection and articular capsular release under brachial plexus anesthesia with ultrasound-guided shoulder joint multisite injection and articular capsular release under brachial plexus anesthesia in combination with rehabilitative therapy

Comparison of ultrasound-guided shoulder joint multisite injection and articular capsular release under brachial plexus anesthesia with ultrasound-guided shoulder joint multisite injection and articular capsular release under brachial plexus anesthesia in combination with rehabilitative therapy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400089112
Enrollment
Unknown
Registered
2024-09-02
Start date
2024-09-30
Completion date
Unknown
Last updated
2024-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adhesive capsulitis of the shoulder

Interventions

Control group:Ultrasound-guided shoulder injection and articular capsular release under brachial plexus anesthesia
Experimental group:Ultrasound-guided shoulder injection and joint capsular release under brachial plexus anesthesia combined with physical rehabilitation

Sponsors

The First Affiliated Hospital of Nanjing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-65 years old; 2. Meet the diagnostic criteria for adhesive capsulitis of the shoulder (chronic onset, persistent dull pain in the shoulder, worsening of pain at night, limitation of active movement of the shoulder joint in multiple directions, and limitation of passive movement of more than 30° in two or more directions, especially limitation of passive external rotation); 3. Pain visual analogue scale (VAS) score =4; 4. Unilateral onset; 5. Disease duration of 9 months or less; 6. No positive findings on ultrasound examination of the affected shoulder joint. 7. Patients voluntarily participated in this trial and signed an informed consent form.

Exclusion criteria

Exclusion criteria: 1. History of surgery or trauma to the affected shoulder; 2. Systemic arthritis (e.g. rheumatoid arthritis, psoriatic arthritis, etc.) or osteoarthritis of the affected shoulder: 3. Systemic infection or localized infection in the area of the puncture; 4. Magnetic resonance or ultrasound examination of the shoulder joint suggesting severe rotator cuff tears 5. Coagulation disorders; 6. Diabetes mellitus with poor glycemic control and abnormal thyroid function; 7. Those with contraindication to glucocorticoid injection or allergy to local anesthetics; 8. People with communication difficulties or mental disorders who are unable to cooperate with the completion of the treatment assessment; 9. People with severe liver and kidney function impairment, cardiovascular and cerebrovascular diseases; 10. Those who have had a history of glucocorticoid injection in the affected shoulder within the last 6 months; 11. Pregnant women; 12. Tumor patients; 13. People with severe osteoporosis; 14. Combined with other diseases that cause shoulder pain.

Design outcomes

Primary

MeasureTime frame
American Shoulder and Elbow Surgeons Score;

Secondary

MeasureTime frame
Visual Analog Scale;12-Item Short Form Survey;Thickness of subglenohumeral joint capsule;

Countries

China

Contacts

Public ContactPan Yinbing

The First Affiliated Hospital of Nanjing Medical University

panyinbing@sina.com+86 139 5209 8007

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026